Krsnaa Diagnostics Ltd
Krsnaa Diagnostics Ltd provides a range of technology-enabled diagnostic services such as imaging, clinical laboratory, and teleradiology services to hospitals, medical colleges, and community health centers across India with an extensive network across non-metro and lower-tier cities and towns.[1]
- Market Cap ₹ 2,037 Cr.
- Current Price ₹ 631
- High / Low ₹ 789 / 449
- Stock P/E 34.8
- Book Value ₹ 252
- Dividend Yield 0.44 %
- ROCE 10.1 %
- ROE 7.52 %
- Face Value ₹ 5.00
Pros
Cons
- Promoter holding is low: 27.0%
- Company has a low return on equity of 10.5% over last 3 years.
- Dividend payout has been low at 12.8% of profits over last 3 years
- Debtor days have increased from 72.1 to 110 days.
- Working capital days have increased from 47.0 days to 131 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
36 | 57 | 108 | 147 | 258 | 396 | 455 | 464 | 590 | |
35 | 42 | 169 | 87 | 373 | 302 | 320 | 340 | 444 | |
Operating Profit | 0 | 15 | -62 | 60 | -114 | 94 | 135 | 124 | 146 |
OPM % | 1% | 26% | -57% | 41% | -44% | 24% | 30% | 27% | 25% |
3 | 4 | 3 | 2 | 13 | 265 | 15 | 19 | 17 | |
Interest | 6 | 6 | 8 | 16 | 25 | 26 | 18 | 8 | 16 |
Depreciation | 5 | 10 | 18 | 26 | 32 | 37 | 41 | 54 | 75 |
Profit before tax | -7 | 2 | -84 | 21 | -158 | 295 | 90 | 82 | 72 |
Tax % | -6% | 8% | 29% | 40% | 29% | 37% | 21% | 23% | 19% |
-8 | 2 | -60 | 12 | -112 | 185 | 71 | 64 | 59 | |
EPS in Rs | -15.05 | 4.01 | -116.54 | 24.15 | -216.83 | 284.73 | 22.52 | 20.23 | 18.14 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 11% | 14% | 14% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 32% |
3 Years: | 14% |
TTM: | 27% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 36% |
3 Years: | -32% |
TTM: | -8% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 8% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 11% |
Last Year: | 8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 | 6 | 16 | 16 | 16 | |
Reserves | 4 | 6 | 43 | -217 | -17 | 671 | 727 | 799 | |
Preference Capital | 50 | 65 | 141 | 15 | 242 | 0 | 0 | ||
81 | 37 | 189 | 231 | 232 | 41 | 32 | 160 | ||
74 | 128 | 256 | 611 | 388 | 149 | 134 | 197 | ||
Total Liabilities | 163 | 176 | 493 | 630 | 609 | 877 | 909 | 1,172 | |
59 | 116 | 223 | 275 | 309 | 386 | 471 | 647 | ||
CWIP | 20 | 6 | 42 | 9 | 4 | 28 | 25 | 10 | |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
85 | 53 | 228 | 345 | 297 | 463 | 413 | 514 | ||
Total Assets | 163 | 176 | 493 | 630 | 609 | 877 | 909 | 1,172 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
59 | 61 | 38 | 119 | 129 | 75 | 24 | |||
-53 | -201 | -77 | -67 | -241 | -109 | -129 | |||
-37 | 145 | 6 | 20 | 176 | -33 | 84 | |||
Net Cash Flow | -31 | 4 | -33 | 71 | 64 | -66 | -20 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 87 | 91 | 140 | 87 | 69 | 48 | 59 | 110 | |
Inventory Days | 21 | 24 | 89 | 93 | |||||
Days Payable | 76 | 99 | 878 | 203 | |||||
Cash Conversion Cycle | 32 | 15 | -650 | 87 | 69 | 48 | 59 | -0 | |
Working Capital Days | 57 | -43 | -100 | -3 | -23 | -14 | 25 | 131 | |
ROCE % | 7% | -65% | 129% | 18% | 12% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - -Analyst / Institutional Investor Meeting scheduled to be held on July 04, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - -Analyst / Institutional Investor Meeting scheduled to be held on July 03, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
27 Jun - -Analyst / Institutional Investor Meeting scheduled to be held on June 28, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
24 Jun - -Analyst / Institutional Investor Meeting scheduled to be held on June 25, 2024.
- Closure of Trading Window 22 Jun
Annual reports
Concalls
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT REC
-
Jun 2022Transcript PPT
-
Mar 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Nov 2021TranscriptPPT
-
Oct 2021Transcript PPT
Service Offerings
The company is one of India’s fastest‑growing, differentiated diagnostics service providers. Its technology-enabled diagnostic services include imaging (including radiology), pathology/clinical laboratory, and tele‑radiology services. It has proven capabilities and the largest presence in the PPP diagnostics segment and extends its services to private and public hospitals, medical colleges, and community health centers in Pan‑India. [1]